Last $0.0026 USD
Change Today 0.00 / 0.00%
Volume 15.0K
As of 12:12 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

intellect neurosciences inc (ILNS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/14 - $0.01
52 Week Low
08/25/14 - $0.0020
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

intellect neurosciences inc (ILNS) Related Bloomberg News

View More Bloomberg News

intellect neurosciences inc (ILNS) Related Businessweek News

No Related Businessweek News Found

intellect neurosciences inc (ILNS) Details

Intellect Neurosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic agents for the treatment of various neurodegenerative diseases. Its product candidate includes OX1, an orally-administered, brain-penetrating, and naturally-occurring copper-binding small molecule, which has completed Phase I clinical trials for the treatment of Friedreich's Ataxia, and Parkinson’s and Wilson’s diseases. The company’s preclinical products comprise CONJUMAB-A, an antibody drug conjugate for the treatment of proteinopathies; and TOC-1 and RV03 for the treatment of Alzheimer’s disease, as well as other tauopathies, such as Frontotemporal dementia. Its preclinical products also consist of IN-N01, an IgG4 therapeutic antibody that promotes the clearance of monomeric, oligomeric, and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury, as well as in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy, and glaucoma. The company has a research collaboration agreement with MRC Technology, as well as license agreements with University of South Alabama Medical Science Foundation, New York University, AHP Manufacturing BV, and ViroPharma.Intellect Neurosciences, Inc. was founded in 2005 and is based in Englewood Cliffs, New Jersey.

intellect neurosciences inc (ILNS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $109.6K
Total Annual Compensation: $291.5K
Compensation as of Fiscal Year 2013.

intellect neurosciences inc (ILNS) Key Developments

Intellect Neurosciences, Inc. Appoints Elliot Maza as Chief Executive Officer and Chairman of Board of Directors

The Board of Intellect Neurosciences, Inc. announced the appointment of Elliot Maza, JD, CPA, currently CFO and Director, as Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors.

Intellect Neurosciences, Inc. announced delayed 10-Q filing

On 05/14/2014, Intellect Neurosciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Intellect Neurosciences Reports Positive Data from Preclinical Studies of TauC3 Monoclonal Antibody

Intellect Neurosciences, Inc. (ILNS) has achieved proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody, indicating its potential to be disease modifying. The pre-clinical study was carried out in collaboration with the University of California Chancellor's professor and chair, Neurobiology and Behavior School of Biological Sciences and director, Institute for Memory Impairments and Neurological Disorders Dr. Frank LaFerla, as well as Dr. Kim Green and his team. Data secured from the pre-clinical study demonstrated that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau, indicating that the treatment with the peripherally administered antibody had an effect on the brain and is able to be disease modifying. TauC3 targets a fragment of tau protein that is the result of beta-amyloid (Aß) induced cleavage of full-length tau by apoptotic caspase enzymes, early in the disease process leading to neuronal loss. The truncated tau shows increased rates and extents of polymerisation in vitro, compared with wild-type full-length tau. This suggests a role for tau truncation in neurofibrillary tangle formation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILNS:US $0.00 USD 0.00

ILNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILNS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ILNS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLECT NEUROSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at